Cytokinetics, Incorporated
CYTK institutional ownership changes in Q2 2026: 144 institutions opened or added positions, 63 trimmed or exited. CYTK (Cytokinetics, Incorporated) is held by 210 institutional investors as of Q2 2026. Top institutional shareholders: BlackRock, Inc. ($1.7B), Wellington Management Group LLP ($590.5M), Vanguard Portfolio Management LLC ($571.8M). Institutions were buying, on balance. In Q2 2026, 1 member of Congress and 144 funds bought CYTK.
Who's Trading
Latest move
Source dates: Price Nov 6, 2026 · Insiders Nov 3, 2026 · Activists Aug 13, 2026 · Congress Oct 12, 2026
Top Holders
| Action | ||||||
|---|---|---|---|---|---|---|
Increased | 20.1M(+21.4%) | $1.7B | 0.0% | -8.77% | 38 | |
Decreased | 6.9M(-13.5%) | $590.5M | 0.1% | +13.30% | 0 | |
Increased | 6.7M(+14.8%) | $571.8M | 0.0% | -21.51% | 36 | |
Increased | 6.5M(+13.0%) | $553.2M | 0.0% | +23.02% | 35 | |
Increased | 6.1M(+11.5%) | $521.2M | 0.0% | -20.92% | 35 | |
Decreased | 5M(-53.1%) | $428.7M | 0.0% | +48.66% | 0 | |
Increased | 5M(+50.0%) | $425.9M | 3.8% | -25.78% | 80 | |
Increased | 4.6M(+48.3%) | $394.9M | 0.0% | -7.95% | 43 | |
Increased | 3.7M(+15.5%) | $316.3M | 0.0% | +100.54% | 36 | |
Increased | 2.9M(+5.2%) | $243.8M | 2.1% | +69.22% | 55 | |
Increased | 2.3M(+35.7%) | $192M | 0.5% | +4.37% | 47 | |
Increased | 2M(+23.6%) | $166.9M | 0.0% | -21.04% | 37 | |
Decreased | 1.8M(-20.1%) | $150.1M | 0.0% | -1.13% | 0 | |
Increased | 1.7M(+118.8%) | $143.7M | 0.0% | -29.70% | 49 | |
Increased | 1.6M(+14.3%) | $140.3M | 0.0% | +47.44% | 34 | |
Increased | 1.6M(+75.8%) | $139.2M | 0.0% | -19.00% | 46 | |
Increased | 1.6M(+47.4%) | $136.6M | 0.4% | +18.13% | 49 | |
Increased | 1.6M(+153.6%) | $135.3M | 0.1% | -30.80% | 58 | |
Increased | 1.6M(+12.1%) | $133.4M | 0.0% | +26.86% | 34 | |
Increased | 1.5M(+72.4%) | $132M | 0.0% | -17.06% | 45 |
Showing 1-20 of 216
| Insider | Trade | Traded |
|---|---|---|
| Malik Fady Ibraham | Exercise 4K sh | |
| Malik Fady Ibraham | Sell $220K | |
| Blum Robert I | Sell $471K | |
| Blum Robert I | Exercise 8K sh | |
| Malik Fady Ibraham | Exercise 4K sh | |
| Malik Fady Ibraham | Sell $224K | |
| Wysenski Nancy | Vest 97 sh | |
| HENDERSON JOHN T | Vest 352 sh | |
| Harrington Robert Arthur | Vest 195 sh | |
| WIERENGA WENDELL | Vest 97 sh |
| Member | Trade | Traded |
|---|---|---|
| Gilbert Cisneros | Buy $1,001 - $15,000 | |
| Gilbert Cisneros | Buy $1,001 - $15,000 | |
| Gilbert Cisneros | Buy $1,001 - $15,000 | |
| Lisa McClain | Sale $1,001 - $15,000 | |
| Lisa McClain | Buy $1,001 - $15,000 |
| Filer | Stake | Filed |
|---|---|---|
| Wellington Management Group LLP | 5.1% | |
| FMR LLC | 3.9% | |
| FMR LLC | 9.0% | |
| Vanguard Capital Management | 5.2% | |
| The Vanguard Group | 0.0% | |
| T. Rowe Price Investment Management, Inc. | 14.5% | |
| STATE STREET CORPORATION | 4.7% |
CYTKCytokinetics, IncorporatedContinue exploring
Other Healthcare stocks held by institutions
UNHUnitedHealth Group Incorporated
LLYEli Lilly and Company
TMOThermo Fisher Scientific Inc
JNJJohnson & Johnson
DHRDanaher Corporation
ISRGIntuitive Surgical, Inc.
MRKMerck & Company, Inc.
ABBVAbbVie Inc.
BSXBoston Scientific Corporation
ABTAbbott LaboratoriesQuestions investors ask about CYTK
Who owns CYTK?
210 institutional investors held CYTK on June 30, 2026, led by BlackRock, Inc. ($1.7B), Wellington Management Group LLP ($590.5M) and Vanguard Portfolio Management LLC ($571.8M).
How many hedge funds hold CYTK?
210 institutional investors reported CYTK in their 13F filings for the quarter ended June 30, 2026, $10.3B in all. 10 of them are rated Elite.
Are institutions buying or selling CYTK?
Buying, on balance. In Q2 2026, 144 institutions opened or added to positions in CYTK and 63 institutions trimmed or exited.
Are Congress members and hedge funds both buying CYTK?
Yes. In Q2 2026, 1 member of Congress and 144 institutional investors bought CYTK.
Data sourced from four public-disclosure sources: SEC 13F, Form 4, 13D/13G, and House/Senate STOCK Act disclosures. Not financial advice. Full disclaimer